Merus CEO Bill Lundberg

#AS­CO22: Merus looks to beat El­e­va­tion to NRG1+ sum­mit as BLA fil­ing ap­proach­es

CHICA­GO — Merus wants to tack­le a rare ge­nom­ic fu­sion in on­col­o­gy that im­pacts about 5,000 new pa­tients in the US each year, and the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.